熱門資訊> 正文
Alcon收购Aurion Biotech的多数股权
2025-03-27 04:55
- Alcon (ALC) said on Wednesday it has acquired a majority interest in Aurion Biotech, a company into developing advanced cell therapies to treat eye diseases.
- Aurion will continue to operate independently, with full support from Alcon to advance its lead cell therapy candidate, AURN001, into Phase 3 clinical trials in late 2025 for treating corneal edema caused by corneal endothelial disease.
- Through this partnership, Aurion will benefit from Alcon’s expertise in R&D, regulatory affairs, ophthalmic medicine, and commercialization.
- Alongside the acquisition, Aurion’s Board has appointed Arnaud Lacoste, formerly Chief Scientific Officer, as the company’s new CEO, effective immediately.
More on Alcon Inc.
- Alcon Inc. (ALC) Q4 2024 Earnings Call Transcript
- Alcon Inc. 2024 Q4 - Results - Earnings Call Presentation
- Alcon: An Eyecare Leader With Strong Profit Margins, But Overheated Valuation
- Alcon upgraded at BofA Securities to Buy on earnings growth potential
- Alcon agrees to acquire LENSAR for $14.00 per share
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
